Digital Look

Welcome to Digital Look++,
you are not logged in

Indivior (INDV)

Pharma and Biotech

1,681.00p

Trade now with Barclays Stockbrokers

Select chart: EPS | Dividend | Revenue

Period Ending	Period	Revenue ($m)	Pre-tax ($m)	EPS	Dividend
31-Mar-23	Q1	253.00	58.00	32.00¢	n/a

Year Ending	Revenue ($m)	Pre-tax ($m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-18	1,005.00	278.00	185.00¢	3.8	n/a	n/a	n/a	0.0%
31-Dec-19	785.00	180.00	120.00¢	2.0	n/a	-35%	n/a	0.0%
31-Dec-20	647.00	(173.00)	40.00¢	16.9	n/a	-67%	n/a	0.0%
31-Dec-21	791.00	190.00	19.20¢	83.2	n/a	-52%	n/a	0.0%
31-Dec-22	901.00	(95.00)	122.00¢	18.9	0.0	+535%	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-23	1,016.89	215.61	92.87p	18.1	n/a	-5%	n/a	0.0%
31-Dec-24	1,133.11	290.03	134.25p	12.5	0.3	+45%	n/a	0.0%
31-Dec-25	1,292.04	397.10	187.00p	9.0	0.2	+39%	n/a	0.0%

	5 Yr High	5 Yr Low	5 Yr Avg	Curr / Avg
Latest	3.87	2.15	26.70	0.64

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

Find out about IFRS and how this affects the financial infomation for all UK companies.